Showing 8 of 48 recruiting trials for “immunoglobulin-a-nephropathy”
RecruitingNCT05234463 ↗
Study of the Link Between Complement Activation and IgA Nephropathy Severity
Phase 2/3 Open-Label Trial of Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy
🏥 Otsuka Pharmaceutical Development & Commercialization, Inc.📍 1 site📅 Started Apr 2022View details ↗
A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy
Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.
RecruitingNCT04858724 ↗
The Chinese Registry of Prognostic Study of IgA Nephropathy (CRPIGA)
RecruitingNCT05190848 ↗
Correlation of Microbiome and Metabonomics With IgA Nephropathy
Tonsillectomy and Immunosuppression in Caucasian Patients With High-risk IgA-nephropathy
👨⚕️ Vladimir Dobronravov, Professor, MD, PhD, DMedSci, St. Petersburg State Pavlov Medical University📍 2 sites📅 Started Mar 2013View details ↗
RecruitingNCT03001947 ↗
IgA Nephropathy Registration Initiative of High Quality (INSIGHT)
← PreviousPage 3 of 3
Get alerts when new trials open
Create a free account to follow conditions and receive trial notifications.
Create free account →